- POSITIVE
Quarterly Revenue Nureca Sep-2026 Quarterly Revenue is Rs 60 Cr which is growth of 49.2% YoY.
- POSITIVE
Quarterly Net Profit Nureca Sep-2026 Quarterly Net Profit is Rs 4 Cr which is growth of 15.4% YoY.
NSE: NURECA | BSE: 543264
Nureca Live Share Price Today, Share Analysis and Chart
aboutNureca Ltd. is a B2C healthcare and wellness company based in India, specializing in home healthcare monitoring and lifestyle products. The company operates primarily through a digital-first model, leveraging e-commerce platforms to distribute it... Read More
305.006.50(2.18%)
6,064
NSE+BSE Volume
NSE 03 Nov, 2026 3:31 PM (IST)
Mid-range PerformerThese stocks have strong quality. Their reasonable financials and technicals make them potentially attractive to investorsView SimilarEmbed DVM
Please subscribe to view forecaster data
Nureca Stock Price Analysis
Day Price Range2.2% 1 Day return | 305 (LTP) 295.5311 LowHigh |
|---|---|
Week Price Range-1.7% 1 Week return | 305 (LTP) 288320.4 LowHigh |
Month Price Range-12.8% 1 Month return | 305 (LTP) 288348 LowHigh |
52 Week Price Range16.6% 1 Year return | 305 (LTP) 204376 LowHigh |
Competitors/Peers
Quarterly
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Nureca quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Sep '26 | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60 | 42.3 | 36.5 | 41.9 | 40.2 | 36.9 | 33.8 | 28.7 | 35.6 | 29.1 | 18.3 | 28.3 | 34.6 | ||
Operating Exp. | 54.1 | 38 | 41.9 | 37.2 | 35.2 | 35.4 | 31.2 | 31.9 | 35 | 26.2 | 24.3 | 26.6 | 30.3 | |
Operating Profit | 4.6 | 2.4 | -6.5 | 2.4 | 2.6 | -1.1 | 0.6 | -4.7 | -2.7 | -2.9 | -4.8 | -4.3 | 1 | |
Operating Profit Margin % | 7.77% | 6.05% | -18.47% | 6.04% | 6.92% | -3.14% | 1.79% | -17.39% | -8.20% | -12.50% | -24.32% | -19.02% | 3.31% | |
Depr. | 0.8 | 0.6 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | |
Interest | 0.2 | 0.2 | 0.2 | 0.2 | 0.4 | 0.2 | 0.6 | 0.1 | 0.3 | 0.1 | 0.2 | 0.1 | 0.1 | |
Profit Before Tax | 5 | 3.6 | -6.2 | 4.1 | 4.1 | 0.8 | 1.5 | -3.9 | -0.3 | 2.2 | -6.7 | 0.9 | 3.6 | |
Tax | 1.4 | 1.2 | 0.5 | 0.8 | 1 | 0.3 | -0.6 | -0.6 | 0.4 | 1 | -2.3 | 0.8 | 1 | |
Net Profit | 3.6 | 2.4 | -6.6 | 3.2 | 3.1 | 0.6 | 2.1 | -3.3 | -0.7 | 1.2 | -4.4 | 0.2 | 2.6 | |
EPS Adj. latest | 3.6 | 2.4 | -6.6 | 3.2 | 3.1 | 0.6 | 2.1 | -3.3 | -0.7 | 1.2 | -4.4 | 0.2 | 2.6 | |
Net profit TTM | 2.7 | 2.2 | 0.3 | 9 | 2.5 | -1.3 | -0.7 | -7.2 | -3.7 | -0.4 | -2.4 | 0.3 | 0.1 | |
Basic EPS TTM | 2.8 | 2.3 | 0.3 | 9.4 | 2.5 | -1.3 | -0.7 | -7.2 | -3.7 | -0.4 | -2.4 | 0.3 | 0.1 | |
Earnings Transcripts | ||||||||||||||
Results PDF | ||||||||||||||
Result Notes |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Nureca Technical Analysis
Nureca EMA & SMA
Bearish-4
2 bullish, 6 bearish
Bullish2
Bearish6
| 5 Day | 302.3 |
|---|---|
| 10 Day | 307.0 |
| 12 Day | 309.0 |
| 20 Day | 315.3 |
| 26 Day | 318.2 |
|---|---|
| 50 Day | 319.7 |
| 100 Day | 309.6 |
| 200 Day | 295.4 |
Nureca Delivery And Volume
Daily Avg. Delivery Volume %
03 Nov, 2026100.0%
Week100.0%
Month100.0%
Nureca Active Candlesticks
Belt Hold Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator
Nureca Resistance and Support
303.83
Pivot
| First Resistance | 312.2 |
|---|---|
| Second Resistance | 319.3 |
| Third Resistance | 327.7 |
| First Support | 296.7 |
|---|---|
| Second Support | 288.3 |
| Third Support | 281.2 |
| Day RSI | 42.1 |
|---|---|
| Day MACD | -9.2 |
| Day MFI | 42.4 |
| Day MACD Signal Line | -6.9 |
Nureca Beta
| 1 Month | 0.2 |
|---|---|
| 1 Year | 0.9 |
| 3 Month | 0.0 |
|---|---|
| 3 Year | 0.9 |
Nureca Price Change Analysis
↓-12.8%
Over 1 Month
LowHigh
288348
↓-11.2%
Over 3 Months
LowHigh
288376
↑14.4%
Over 6 Months
LowHigh
224.0376
↑16.6%
Over 1 Year
LowHigh
204376
Nureca Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| SWATHITHA SIVAKUMAR | Bulk | Sell | 29 Oct 2025 | 263.96 | 77,761 | NSE |
| AAKRAYA RESEARCH LLP | Bulk | Sell | 15 Jan 2025 | 409.84 | 63,937 | NSE |
| COPTHALL MAURITIUS INVESTMENT LIMITED | Bulk | Purchase | 15 Jan 2025 | 401.94 | 116,711 | NSE |
| AAKRAYA RESEARCH LLP | Bulk | Purchase | 15 Jan 2025 | 409.49 | 63,937 | NSE |
| ELIXIR WEALTH MANAGEMENT PRIVATE LIMITED | Bulk | Sell | 14 Jan 2025 | 363.99 | 65,679 | NSE |
| ELIXIR WEALTH MANAGEMENT PRIVATE LIMITED | Bulk | Purchase | 14 Jan 2025 | 360.28 | 51,679 | NSE |
| ELIXIR WEALTH MANAGEMENT PRIVATE LIMITED | Bulk | Sell | 10 Jan 2025 | 376.30 | 43,548 | NSE |
| NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Sell | 10 Jan 2025 | 368.22 | 64,563 | NSE |
| MUDUPULAVEMULA SURENDRANADHA REDDY | Bulk | Sell | 10 Jan 2025 | 362.41 | 95,867 | NSE |
| NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Purchase | 10 Jan 2025 | 367.89 | 64,563 | NSE |
Nureca Corporate Actions
Nureca Dividend history and yield
Nureca dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Nureca dividend yield over time.
#Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
124 Feb 2022 | 3 | INTERIM | 25 Feb 2022 | Equity Share |
221 Sep 2021 | 2 | FINAL | - | Equity Share |
Nureca Board Meetings
Nureca past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
121 Oct 2026 | Quarterly Results | - |
221 Jul 2026 | Quarterly Results | - |
329 May 2026 | Audited Results | - |
417 Jan 2026 | Quarterly Results & Others | To consider other business matters. |
528 Nov 2025 | Buy Back of Shares | - |
Nureca Corporate Filings
Nureca BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.
| Date | Announcement Title | Details | Links |
|---|---|---|---|
| 03 Nov 2026 | Nureca Ltd - 543264 - Announcement under Regulation 30 (LODR)-Credit Rating | Intimation about Credit Rating | |
| 22 Oct 2026 | Nureca Ltd - 543264 - Announcement under Regulation 30 (LODR)-Newspaper Publication | Copy of Newspaper Publication | |
| 21 Oct 2026 | Nureca Ltd - 543264 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | Nureca records highest quarterly revenue in last 20 quarters ;Q2 revenue rises 55% to Rs. 58.53 crore . | |
| 21 Oct 2026 | Nureca Ltd - 543264 - Board Meeting Outcome for Un-Audited Financial Results For The Quarter And Half Year Ended 30Th September,2026 | Un-audited Financial results for the quarter and half year ended 30th September,2026 | |
| 17 Oct 2026 | Nureca Ltd - 543264 - Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements )Regulations,2015 | Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. |
Nureca Documents
Nureca Earnings Call
Nureca earnings calls, including management commentary and AI-generated summaries.
Nureca Annual Reports
Nureca financials, including annual results, balance sheets, and cash flow statements.
Nureca Credit Ratings
Nureca credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.
| Date | Rating Agency | Company Name | Description | Links |
|---|---|---|---|---|
| 01 Nov 2026 | crisil ratings | Nureca Limited | Nureca Limited:'Crisil BB+ / Stable / Crisil A4+ ' assigned to Bank Debt | Link |
Nureca Investor Presentations
Nureca investor presentations, including business updates, financial insights, and strategic initiatives.
| Date | Report Title | Links |
|---|---|---|
| 21 Jul 2026 | Nureca Ltd - 543264 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
| 29 May 2026 | Nureca Ltd - 543264 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
| 18 Jan 2026 | Nureca Ltd - 543264 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
| 17 Jan 2026 | Nureca Ltd - 543264 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
| 16 Oct 2025 | Nureca Ltd - 543264 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
Nureca - Company Profile
Nureca Management Structure
Nureca management structure with salaries, total experience, and qualifications.
Nureca Board of Directors
Nureca Board of directors with salaries, total experience, and qualifications.
Website: www.nureca.com
About the company - Business Profile
Nureca Ltd. is a B2C healthcare and wellness company based in India, specializing in home healthcare monitoring and lifestyle products. The company operates primarily through a digital-first model, leveraging e-commerce platforms to distribute its products under its flagship brand, Dr Trust. Nureca focuses on chronic disease management and wellness, offering a diverse portfolio of over 150 products that comply with international safety standards, including US FDA and CE certifications.
Key Points
- Key Facts: Founded in 2016, Nureca Ltd. is headquartered in Mumbai, India. It was listed on the Indian stock exchanges in 2021. Its flagship brand is Dr Trust, complemented by other brands like Dr Physio and Trumom.
- Operations and Resources: The company follows an asset-light business model. It primarily focuses on product ideation, research, and quality assurance. While most of its sales are online, it has established a physical distribution network across 16 states. In April 2022, its wholly-owned manufacturing subsidiary, Nureca Technologies Pvt. Ltd. (NTPL), began operations to manufacture products like BP monitors, nebulizers, and electric massagers.
- Privatization and Ownership: Nureca is a promoter-led public company. As of recent filings, the promoter group maintains a significant controlling stake, with the remaining shares held by the public and institutional investors.
- Market and Significance: Nureca serves the growing home healthcare market in India, which is driven by an increasing prevalence of chronic diseases and a shift toward proactive health monitoring. Its products are vital for managing conditions like hypertension and diabetes at home.
- Revenue Breakdown: For the financial year ended March 31, 2025, Nureca reported a consolidated revenue of ₹109.7 crore. The business is concentrated in the domestic Indian market, which is treated as a single geographical segment.
- Sustainability and Innovation: The company integrates digital technology into its devices, allowing users to analyze health data via connected apps. Future goals include expanding its product range in the preventive healthcare space and deepening its presence in the chronic disease management market.
Business Model and Capabilities
Nureca utilizes a Direct-to-Consumer (D2C) model, with approximately 93% to 97% of its revenue generated through online channels, including its own website and major e-commerce platforms. This digital-first strategy allows for high scalability and direct customer engagement. The company is proficient at identifying consumer needs in the wellness space and rapidly bringing certified products to market.
- Key Products and Technology:
- Home Healthcare: Digital blood pressure monitors, glucometers, and infrared thermometers.
- Wellness: Electric massagers, nebulizers, and steamers.
- Mother and Baby Care: Electric breast pumps and baby carriers.
- Technology: Development of data analytics tools that connect to health monitoring devices for personalized health tracking.
- Employee Count and Trends: While specific total employee counts are not highlighted, the company emphasizes a lean structure with a focused quality assurance team to manage its asset-light operations.
- Major Subsidiaries: Nureca Technologies Private Limited is the primary subsidiary focused on local manufacturing to support the "Make in India" initiative and ensure supply chain control.
- Strategic Initiatives: Current efforts are focused on expanding the offline retail footprint to reach a broader customer base and diversifying the product portfolio into high-growth areas like pet health monitoring (e.g., Pet Infrared Thermometers).